Al-Shakliah Nasser S, Kadi Adnan A, Aljohar Haya I, AlRabiah Haitham, Attwa Mohamed W
Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University P.O. Box 2457 Riyadh 11451 Saudi Arabia
RSC Adv. 2022 Jul 21;12(32):20991-21003. doi: 10.1039/d2ra02848d. eCollection 2022 Jul 14.
Zorifertinib (AZD-3759; ZFB) is a potent, novel, oral, small molecule used for the treatment of non-small cell lung cancer (NSCLC). ZFB is Epidermal Growth Factor Receptor (EGFR) inhibitor that is characterized by good permeability of the blood-brain barrier for (NSCLC) patients with EGFR mutations. The present research reports the profiling of , and reactive metabolites of ZFB. Prediction of vulnerable metabolic sites and reactivity pathways (cyanide and GSH) of ZFB were performed by WhichP450™ module (StarDrop software package) and XenoSite reactivity model (XenoSite Web Predictor-Home), respectively. ZFB metabolites were done by incubation with isolated perfused rat liver hepatocytes and rat liver microsomes (RLMs). Extraction of ZFB and its related metabolites from the incubation matrix was done by protein precipitation. metabolism was performed by giving ZFB (10 mg kg) through oral gavage to Sprague Dawley rats that were housed in metabolic cages. Urine was collected at specific time intervals (0, 6, 12, 18, 24, 48, 72, 96 and 120 h) from ZFB dosing. The collected urine samples were filtered then stored at -70 °C. -Methyl piperazine ring of ZFB undergoes phase I metabolism forming iminium intermediates that were stabilized using potassium cyanide as a trapping agent. Incubation of ZFB with RLMs were performed in the presence of 1.0 mM KCN and 1.0 mM glutathione to check reactive intermediates as it is may be responsible for toxicities associated with ZFB usage. For metabolites there were six phase I metabolites, three phase II metabolites, seven reactive intermediates (four GSH conjugates and three cyano adducts) of ZFB were detected by LC-IT-MS. For metabolites there were six phase I and three phase II metabolites of ZFB were detected by LC-IT-MS. and phase I metabolic pathways were -demethylation, -demethylation, hydroxylation, reduction, defluorination and dechlorination. phase II metabolic reaction was direct sulphate and glucuronic acid conjugation with ZFB.
佐利替尼(AZD - 3759;ZFB)是一种强效、新型的口服小分子药物,用于治疗非小细胞肺癌(NSCLC)。ZFB是一种表皮生长因子受体(EGFR)抑制剂,其特点是对患有EGFR突变的NSCLC患者具有良好的血脑屏障通透性。本研究报告了ZFB的代谢产物、反应性代谢产物的分析情况。分别通过WhichP450™模块(StarDrop软件包)和XenoSite反应性模型(XenoSite Web Predictor - Home)对ZFB的易损代谢位点和反应途径(氰化物和谷胱甘肽)进行预测。ZFB的代谢产物通过与分离的灌注大鼠肝脏肝细胞和大鼠肝脏微粒体(RLMs)孵育来完成。通过蛋白质沉淀从孵育基质中提取ZFB及其相关代谢产物。通过对饲养在代谢笼中的Sprague Dawley大鼠经口灌胃给予ZFB(10 mg/kg)来进行体内代谢研究。在特定时间间隔(0、6、12、18、24、48、72、96和120小时)收集ZFB给药后的尿液。收集的尿液样本经过过滤后储存在 -70°C。ZFB的N - 甲基哌嗪环经历I相代谢形成亚胺中间体,使用氰化钾作为捕获剂使其稳定。在1.0 mM KCN和1.0 mM谷胱甘肽存在的情况下,将ZFB与RLMs孵育,以检查反应性中间体,因为其可能是与ZFB使用相关毒性的原因。对于体外代谢产物,通过液相色谱 - 离子阱 - 质谱(LC - IT - MS)检测到ZFB有六种I相代谢产物、三种II相代谢产物、七种反应性中间体(四种谷胱甘肽缀合物和三种氰基加合物)。对于体内代谢产物,通过LC - IT - MS检测到ZFB有六种I相和三种II相代谢产物。I相代谢途径为N - 去甲基化、O - 去甲基化、羟基化、还原、脱氟和脱氯。II相代谢反应是ZFB直接与硫酸盐和葡萄糖醛酸结合。